Associated Papers
Rare variants and founder effect in the Beauce region of Quebec.
Gagnon M et al.
Communications Biology, 2025
Frequency enrichment of coding variants in a French-Canadian founder population and its implication for inflammatory bowel diseases.
Bhérer C et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
In Silico Binary Classification of Catalytic Function (Unaffected or Impaired) of Flavin-Containing Monooxygenase 3 (FMO3) Variants and in Vitro Validation Using New Variants Found in a Japanese Genome Resource Database.
Shimizu M et al.
Biological & Pharmaceutical Bulletin, 2025
Exploring Trimethylaminuria: Genetics and Molecular Mechanisms, Epidemiology, and Emerging Therapeutic Strategies.
Sidoti A et al.
Biology, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Rare but impaired flavin-containing monooxygenase 3 (FMO3) variants reported in a recently updated Japanese mega-databank of genome resources.
Shimizu M et al.
Drug Metabolism and Pharmacokinetics, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
A Panel-Agnostic Strategy 'HiPPo' Improves Diagnostic Efficiency in the UK Genomic Medicine Service.
Seaby EG et al.
Healthcare (basel, Switzerland), 2023
A family study of compound variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects found by urinary phenotyping for trimethylaminuria.
Shimizu M et al.
Drug Metabolism and Pharmacokinetics, 2023
A panel-agnostic strategy 'HiPPo' improves diagnostic efficiency in the UK Genome Medicine Service.
Seaby EG et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies.
Cordo' V et al.
Nature Communications, 2022
MicroSEC filters sequence errors for formalin-fixed and paraffin-embedded samples.
Ikegami M et al.
Communications Biology, 2021
A series of simple detection systems for genetic variants of flavin-containing monooxygenase 3 (FMO3) with impaired function in Japanese subjects.
Shimizu M et al.
Drug Metabolism and Pharmacokinetics, 2021
Adaptive Modelling of Mutated FMO3 Enzyme Could Unveil Unexplored Scenarios Linking Variant Haplotypes to TMAU Phenotypes.
Alibrandi S et al.
Molecules (basel, Switzerland), 2021
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects identified by phenotyping for trimethylaminuria and found in a database of genome resources.
Shimizu M et al.
Drug Metabolism and Pharmacokinetics, 2021
Comprehensive germline genomic profiles of children, adolescents and young adults with solid tumors.
Akhavanfard S et al.
Nature Communications, 2020
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Genetic and Nongenetic Factors Associated with Protein Abundance of Flavin-Containing Monooxygenase 3 in Human Liver.
Xu M et al.
The Journal of Pharmacology and Experimental Therapeutics, 2017
Targeted sequencing identifies genetic polymorphisms of flavin-containing monooxygenase genes contributing to susceptibility of nicotine dependence in European American and African American.
Zhang TX et al.
Brain and Behavior, 2017
GESPA: classifying nsSNPs to predict disease association.
Khurana JK et al.
Bmc Bioinformatics, 2015
Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities.
Yamazaki H et al.
Biochemical Pharmacology, 2013
Trimethylaminuria: an under-recognised and socially debilitating metabolic disorder.
Christodoulou J
Journal of Paediatrics and Child Health, 2012
A common FMO3 polymorphism may amplify the effect of nicotine exposure in sudden infant death syndrome (SIDS).
Poetsch M et al.
International Journal of Legal Medicine, 2010
Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.
Krueger SK et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2009
Flavin-containing monooxygenase 3 and human disease.
Motika MS et al.
Expert Opinion on Drug Metabolism & Toxicology, 2007
Functional characterization of genetic variants of human FMO3 associated with trimethylaminuria.
Yeung CK et al.
Archives of Biochemistry and Biophysics, 2007
Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis.
Hisamuddin IM et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2005
Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.
Krueger SK et al.
Pharmacology & Therapeutics, 2005
Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis.
Hisamuddin IM et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2004
The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development.
Cashman JR
Drug Discovery Today, 2004
Trimethylaminuria and a human FMO3 mutation database.
Hernandez D et al.
Human Mutation, 2003
Deleterious mutations in the flavin-containing monooxygenase 3 (FMO3) gene causing trimethylaminuria.
Zhang J et al.
Pharmacogenetics, 2003
Fish odour syndrome with features of both primary and secondary trimethylaminuria.
Fraser-Andrews EA et al.
Clinical and Experimental Dermatology, 2003
Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation.
Cashman JR et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2002
A novel deletion in the flavin-containing monooxygenase gene (FMO3) in a Greek patient with trimethylaminuria.
Forrest SM et al.
Pharmacogenetics, 2001
Compound heterozygosity for missense mutations in the flavin-containing monooxygenase 3 (FM03) gene in patients with fish-odour syndrome.
Dolphin CT et al.
Pharmacogenetics, 2000
Population-specific polymorphisms of the human FMO3 gene: significance for detoxication.
Cashman JR et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2000
Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism.
Sachse C et al.
Clinical Pharmacology and Therapeutics, 1999
Two novel mutations of the FMO3 gene in a proband with trimethylaminuria.
Akerman BR et al.
Human Mutation, 1999